Results for glucose nuchter translation from Dutch to English

glucose nuchter
glucose fasting

verminderde nuchtere glucose
impaired fasting glucose

nuchtere glucose, mg/dl
fasting glucose, mg/dl

nuchter bloed glucose abnormaal
fasting blood glucose abnormal

de verbetering in nuchtere glucose hield aan gedurende de langste studieduur van 104 weken.
the improvement in fasting glucose was sustained through the longest study duration of 104 weeks.

de verbeterde glykemische controle is geassocieerd met dalingen van zowel het nuchtere als het postprandiale glucose.
the improved glycaemic control is associated with reductions in both fasting and post- prandial glucose.

meting van nuchtere waarden van serumlipiden en bloed-glucose dient overwogen te worden.
consideration should be given to measurement of fasting serum lipids and blood glucose.

dit leidt tot een glucose-afhankelijke toename van insulineafgifte waardoor nuchtere en postprandiale glucoseconcentraties worden verlaagd.
this results in a glucose-dependent increase in insulin secretion, thus reducing fasting and post-prandial blood glucose concentrations.

linagliptine vertoonde tevens significante verbeteringen in nuchtere plasmaglucose (fpg) en glucose 2 uur postprandiaal (ppg) in vergelijking met placebo.
linagliptin also showed significant improvements in fasting plasma glucose (fpg), and 2-hour post-prandial glucose (ppg) compared to placebo.

linagliptine vertoonde tevens significante verbeteringen in nuchtere plasmaglucose (fpg) en glucose 2 uur postprandiaal (ppg), vergeleken met placebo.
linagliptin also showed significant improvements in patients fasting plasma glucose (fpg), and 2-hour post-prandial glucose (ppg), compared to placebo.

verbeteringen werden gezien voor nuchtere glucose, nuchtere insuline, homa-ir en percentage patiënten die nooddiabetesmedicatie nodig hadden voor patiënten die behandeld werden met naltrexon/bupropion versus placebo.
improvements were observed for fasting glucose, fasting insulin, homa-ir and percent of subjects requiring rescue diabetes medicinal products for subjects treated with naltrexone / bupropion vs. placebo.